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rivalent inﬂuenza vaccines (QIVs) contain one additional B strain com-
pared with trivalent inﬂuenza vaccines (TIVs). Objective: To examine the
expected public health impact, budget impact, and incremental cost-
effectiveness of QIV versus TIV in the United States.Methods: A dynamic
transmissionmodel was used to predict the annual incidence of inﬂuenza
over the 20-year-period of 2014 to 2034 under either a TIV program or a
QIV program. A decision tree model was interfaced with the transmission
model to estimate the public health impact and the cost-effectiveness of
replacing TIV with QIV from a societal perspective. Our models were
informed by published data from the United States on inﬂuenza compli-
cation probabilities and relevant costs. The incremental vaccine price of
QIV as compared with that of TIV was set at US $5.40 per dose. Results:
Over the next 20 years, replacing TIV with QIV may reduce the number of
inﬂuenza B cases by 27.2% (16.0 million cases), resulting in the preventionee front matter Copyright & 2016, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).
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ndence to Pieter T. de Boer, Department of Pharmaof 137,600 hospitalizations and 16,100 deaths and a gain of 212,000 quality-
adjusted life-years (QALYs). The net societal budget impact would be US
$5.8 billion and the incremental cost-effectiveness ratio US $27,411/QALY
gained. In the probabilistic sensitivity analysis, 100% and 96.5% of the
simulations fell below US $100,000/QALY and US $50,000/QALY, respec-
tively. Conclusions: Introducing QIV into the US immunization program
may prevent a substantial number of hospitalizations and deaths. QIV is
also expected to be a cost-effective alternative option to TIV.
Keywords: cost-effectiveness, inﬂuenza, quadrivalent inﬂuenza
vaccine, vaccination.
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What is already known about the topic?
Recently approved quadrivalent inﬂuenza vaccines (QIVs) contain
one extra B lineage as compared with trivalent inﬂuenza vaccines
(TIVs). Therefore, QIVs offer improved protection during seasons
with cocirculation of both type-B lineages or when TIV is
mismatched against the sole circulating inﬂuenza B strain. A
number of static models have predicted that shifting from TIV to
QIV is a potential cost-effective intervention in the United States.
What does the article add to existing knowledge?
We use a dynamic model to study the cost-effectiveness of
switching from TIV to QIV in the United States. Static models
do not incorporate disease transmission dynamics, whereas
dynamic models do (herd effects). Ignoring disease transmission
can be a signiﬁcant source of bias in infectious disease modeling
studies. Moreover, some previous cost-effectiveness studiesignored cross-protection of TIV against the mismatched inﬂu-
enza B lineage.
What insights does the article provide for informing health care–related
decision making?
Shifting from TIV to QIV is expected to reduce the number of
inﬂuenza B cases by 27.2% over the next 20 years. Using the
societal perspective, the incremental cost-effectiveness ratio was
estimated at US $27,411 per quality-adjusted life-year gained. The
probabilistic sensitivity analysis showed that the results are
robust. This article illustrates that, using a dynamic model, cost-
effectiveness is estimated to be below a potential willingness-to-
pay threshold of US $50,000/quality-adjusted life-year gained.Introduction
Seasonal inﬂuenza is a viral infectious disease caused by inﬂu-
enza type-A (H1N1 and H3N2) viruses or inﬂuenza type-B virusesociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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represent on average 24% of viral isolates in the United States
and from the 2001-2002 season to the present, both B lineages
have cocirculated each season at varying levels and with no
regularity [1]. In the United States, the average annual public
health burden of seasonal inﬂuenza (types A and B) is estimated
at 24,000 deaths and 95,000 hospital admissions; however, in
severe seasons, this can increase to 49,000 and 270,000, respec-
tively [2,3]. Also, the economic burden of inﬂuenza is signiﬁcant.
Annual inﬂuenza-related medical costs in the United States have
been estimated at US $10 billion and productivity costs at US $16
billion [4]. Seasonal vaccination against inﬂuenza is regarded as
the most effective strategy to prevent inﬂuenza disease [5].
Traditional inﬂuenza vaccines are trivalent, containing strains
of two inﬂuenza A subtypes (one of each H1N1 and H3N2) and
one strain of an inﬂuenza B lineage (Victoria or Yamagata),
according to recommendations of the World Health Organization.
However, over the decade 2001 through 2012, mismatches
between the circulating B lineage and the B strain of the vaccine
occurred in 5 of the 10 seasons in the United States because of the
cocirculation of both inﬂuenza B lineages [1]. Two recent meta-
analysis have demonstrated that TIV offers suboptimal protec-
tion when there is a mismatch between circulating inﬂuenza B
and B vaccine strains (B-lineage vaccine efﬁcacy is 71%–77%
when TIV inﬂuenza B is lineage matched and 46%–49% when
mismatched) [6,7].
To address the problem of inﬂuenza B matching, quadrivalent
inﬂuenza vaccines (QIVs) were developed and licensed in the US
market in 2012 [8]. In addition to strains of the two inﬂuenza A
subtypes, QIVs contain strains from both type-B lineages (Victoria
and Yamagata). The US Centers for Disease Control and Preven-
tion (CDC) estimated that QIV might have prevented on average
340,000 inﬂuenza cases, 2,700 hospitalizations, and 170 deaths
within the seasons 2001-2002 to 2008-2009 [9]. Moreover, two
economic evaluations demonstrated that the cost-effectiveness
of shifting from TIV to QIV was favorable [10–12].
However, published economic evaluations of QIV versus TIV
in the United States so far are based on static models. The static
approach assumes a constant risk of infection and does not
incorporate the indirect protection that the successfully immu-
nized proportion of the population provides to those individuals
who are still susceptible, by reducing the risk of transmission
(herd effects). Dynamic models simulate disease transmission by
taking into account contact patterns between humans and the
risk of transmission per contact, which allows the model to
account for herd effects [13]. Because inﬂuenza vaccina-
tion impacts disease transmission, the dynamic approach can
be regarded as the more appropriate approach to quantify theFig. 1 – Flow diagram of the ecoepidemiological and economic impact of replacing TIV by QIV
[14]. The aim of this study was to assess the cost-effectiveness of
QIV versus TIV for seasonal vaccination in the United States on
the basis of a dynamic modeling approach.Methods
Overview
The cost-effectiveness model uses an age-structured dynamic
transmission model to estimate the impact of QIV over TIV in
terms of clinical outcomes, costs, and health effects. Clinical
outcomes included outpatient visits, hospitalizations, and
deaths. Costs were assessed from the third-party payer’s (TPP’s)
perspective, considering reimbursed direct medical costs only, as
well as from the societal perspective, which also accounts for
out-of-pocket-paid over-the-counter medication and indirect
costs due to productivity losses. Final outcomes of the study
were incremental costs per quality-adjusted life-year (QALY)
gained and incremental costs per life-year (LY) gained.
Model Design
The dynamic transmission model developed by Crepey et al. [15]
was used to estimate age-stratiﬁed numbers of symptomatic
inﬂuenza B cases under the QIV and TIV strategies. The model
is a variation on the compartmental SEIR model, where individ-
uals can be susceptible to infection (S), exposed but not infectious
(E), infectious (I), or recovered (R) from an infection and therefore
immune for a certain time period. A vaccination compartment
was added to account for individuals effectively protected from
infection by vaccination. The model accounted for cross-protec-
tion, that is, the protection that vaccination against or natural
infection by a B lineage offers against the opposite B lineage.
A more detailed description of the dynamic model and main
input parameters can be found in Supplemental document A and
Appendix Table 1 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2016.05.012.
For the economic model, we used an age-structured decision
tree model (Fig. 1), developed in Excel 2010 and linked to the
dynamic model described above. The output of the dynamic
model, age-stratiﬁed symptomatic inﬂuenza cases, served as
input to the economic model. First, the age groups of the dynamic
model were recategorized in the economic model to align with
available data on economic parameters (0–23 months, 2 years, 3–4
years, 5–11 years, 12–17 years, 18–49 years, 50–64 years, 65þ
years), using age-distribution data of the US population [16]. Next,nomic decision tree model.
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risk (NHR) patients and high-risk (HR) patients on the basis of the
presence of chronic disease [17]. Then, cases were divided into
four categories (no medical attention, outpatient visit, hospital
admission, and death) on the basis of relevant medical compli-
cation probabilities reported by Molinari et al. [4]. For children
younger than 18 years, outpatient visits were further subdivided
between uncomplicated cases, cases with otitis media, and cases
with pneumonia/other complication following the model design
of Prosser et al. [18]. We ignored the adverse events of vaccine in
our model because the safety proﬁle of TIV and QIV was found to
be similar [19–21].
Probabilities
Table 1 lists all relevant probabilities included in the model.
Health status
Age-speciﬁc proportions of the US population at high risk of
complications were derived from Molinari et al. [4]. HR statuses
were based on the Advisory Committee on Immunization Prac-
tices recommended groups for inﬂuenza vaccination [22]. Nota-
bly, being 65 years or older was not sufﬁcient on its own for an
individual to qualify as being at high risk. Because the dynamic
transmission model did not stratify by health status, we divided
the symptomatic inﬂuenza cases between HR and NHR according
to the prevalence of HR in the different age groups. This assumes
that HR and NHR patients were at equal risk of inﬂuenza
infection and of developing symptomatic inﬂuenza. To correct
for difference in vaccination coverage between HR and NHR
(higher in the HR group), we adjusted the division of inﬂuenza
cases between NHR and HR according to NHR-/HR-speciﬁc vac-
cine coverages [23,24].
Primary care
The probability of an outpatient visit per inﬂuenza B case was
based on published studies [4,18]. In these studies, it was
assumed that the probability of an outpatient visit for an HR
patient was estimated to be approximately twice that of an NHR
patient, except for elderly, where the corresponding factor was
estimated at 1.3. For children, outpatient visits were further
divided between uncomplicated cases and complicated cases,
which were deﬁned as cases presenting with otitis media and
pneumonia/other complications [18].
Hospitalizations and mortality
Consistent with primary care data source, probabilities of hospi-
talization and death were derived from the same source [4].
These probabilities were based on 1980-2001 data and estimated
by modeling excess hospitalizations and deaths using Interna-
tional Classiﬁcation of Diseases-9 codes for underlying respiratory
and circulatory conditions. No distinction between risk groups
was available here, so this was not included in the base-case
analysis. However, a scenario with higher probability of hospital-
ization and death for HR individuals was explored in the sensi-
tivity analysis.
Costs
Medical costs
Costs are presented in Table 1 and adjusted to 2013 US dollars
using the Consumer Price Index [25]. All medical costs were
derived from published US studies. Cost data of outpatient visits
included outpatient service claims as well as pharmaceutical
claims and laboratory testing [4,18]. For children, costs of a
hospitalization included diagnostics, therapeutics (includingprescriptions), room costs, and physician services [18,26]. For
adults, total costs of hospitalized patients and deaths were based
on all direct costs of 2 weeks before admission to 30 days after
admission, including inpatient costs, outpatients cost, and phar-
maceutical claims [4]. Notably, the assumption was that all
patients dying received some hospital care before they died.
Costs of over-the-counter medication were retrieved from pub-
lished sources [4,18,27], and counted for all inﬂuenza cases,
including cases that did not seek medical attention.
Vaccination costs
Total yearly number of administered vaccinations was calculated
by multiplying the age-speciﬁc coverage rates with the corre-
sponding population sizes, as already present in the underlying
dynamic model. The Advisory Committee on Immunization
Practices recommends that children younger than 8 years receiv-
ing inﬂuenza vaccination for the ﬁrst time should be vaccinated
twice, although this advice is likely not strictly adhered to [22]. As
such, and in accordance with previous modeling studies, the
number of vaccines given to children aged 6 to 23 months, 2
years, and 3 to 4 years was multiplied by 2, 1.5, and 1.33,
respectively [18]. Vaccine prices of TIV and QIV for the public
and private markets were obtained from the CDC vaccine price
list of 2013 [28]. We assumed that 50% of children younger than
12 years, 30% of adolescents aged between 12 and 18 years, and
10% of the adults obtain the vaccine funded under the public
price and the remainder by paying private market prices [29]. No
administration costs were included in this analysis because these
were assumed to be equal in both alternatives.
Indirect costs
Age- and health-status–speciﬁc productivity losses were derived
from Molinari et al. [4]. Up to the age of 17 years, lost productivity
was counted as parental work loss, whereas for cases 18þ years
old work loss was assigned to the cases themselves. Following
the US Panel on Cost Effectiveness in Health and Medicine, we
used the friction costs method approach to count productivity
losses [30]. This approach limits productivity losses of long-term
absence to a friction period, assuming that employees have been
replaced after this initial period [31]. The friction period was set
at 40 days, which comprises 20 days to make the decision
whether an employee has to be replaced and another 20 days
to ﬁll the vacancy [32,33]. In line with the friction costs method,
we multiplied the number of workdays lost with the elasticity
adjustment factor, as the proportion of reduction in effective
labor time due to absence will be less than 1 due to, for example,
a company’s internal labor reserves [34]. Because we were not
able to identify data on US elasticity of labor, as such, we used an
internationally suggested elasticity of 0.8 [35]. Finally, adjusted
productivity losses were calculated by multiplying the lost pro-
ductivity days with age-speciﬁc daily earnings [36]. These daily
earnings were further adjusted for age-speciﬁc labor participation
rates [16]. For productivity losses of caregivers, we used average
daily earnings of the age group 25 to 54 years.
Health Effects
QALY losses of inﬂuenza and its complications are presented in
Table 1. For children younger than 18 years, QALY loss for
uncomplicated inﬂuenza was estimated at 0.005 per episode
[37]. This was based on time trade-off questions for parents on
uncomplicated inﬂuenza of their child. Additional QALY losses
for children with otitis media, pneumonia, and hospitalized
inﬂuenza were derived from a pneumococcal study, and were
estimated at 0.042, 0.046, and 0.076, respectively [38]. QALY loss of
a nonhospitalized inﬂuenza episode in the adult population was
Table 1 – Input of the economic model.
Variable Base case DSA range Type of distribution Reference
Proportion at HR of serious complications
0–4 y 0.052 NA NA [4]
5–17 y 0.106 NA NA
18–49 y 0.149 NA NA
50–64 y 0.330 NA NA
65þ y 0.512 NA NA
Probability of outpatient visit/ﬂu infection
0–1 y
NHR 0.50 0.17–0.83 Beta (3.9;3.9) [18]
HR 1 2  NHR 1.8  NHR
2 y
NHR 0.47 0.15–0.81 Beta (3.7;4.1)
HR 0.94 2  NHR 1.9  NHR
3–4 y
NHR 0.43 0.12–0.78 Beta (3.3;4.4)
HR 0.86 2  NHR 2.1  NHR
5–11 y
NHR 0.28 0.11–0.50 Beta (5.4;14)
HR 0.56 2  NHR 2  NHR
12–17 y
NHR 0.24 0.06-0.50 Beta (3.2;10)
HR 0.48 2  NHR 2  NHR
18–49 y
NHR 0.31 0.28–0.34 Beta (338;752) [4]
HR 0.62 2  NHR 2  NHR
50–64 y
NHR 0.31 0.28–0.34 Beta (338;752)
HR 0.62 2  NHR 2  NHR
65þ y
NHR 0.62 0.57–0.67 Beta (200;122)
HR 0.82 1.3  NHR 1.3  NHR
Probability of otitis media/inﬂuenza-related outpatient visit
0–1 y
All-risk 0.63 0.33–0.80 Beta (9.6;5.6) [18]
2 y
All-risk 0.58 0.27–0.80 Beta (7.2;5.2)
3–4 y
All-risk 0.39 0.17–0.60 Beta (7.3;11)
5–11 y
All-risk 0.23 0.05–0.50 Beta (2.9;9.6)
12–17 y
All-risk 0.15 0.01–0.40 Beta (1.8;10)
Probability of pneumonia or other complication/inﬂuenza-related outpatient visit
0–1 y
All-risk 0.20 0.04–0.5 Beta (2.1;8.5) [18]
2 y
All-risk 0.15 0.02–0.4 Beta (1.9;11)
3–4 y
All-risk 0.15 0.02–0.4 Beta (1.9;11)
5–11 y
All-risk 0.11 0.02–0.3 Beta (2.0;16)
12–17 y
All-risk 0.08 0.01–02 Beta (2.4;28)
Probability of hospitalization/ﬂu case
0–4 y
All-risk 0.0141 0.0049–0.0233 Beta (8.9;619) [4]
5–17 y
All-risk 0.0006 0.0002–0.001 Beta (9.0;14,981)
18–49 y
All-risk 0.0042 0.0015–0.0069 Beta (9.0;2,124)
50–64 y
All-risk 0.0193 0.00676–0.0318 Beta (8.9;452)
65þ y
All-risk 0.0421 0.0147–0.0695 Beta (8.6;196)
Probability of death/ﬂu case
0–4 y
All-risk 0.00004 0.00002–0.00006 Beta (16;399,967) [4]
5–17 y
All-risk 0.00001 0.000008–0.000012 Beta (100;9,999,799)
18–49 y
All-risk 0.00009 0.00003–0.00015 Beta (9;99,981)
50–64 y
All-risk 0.00134 0.000458–0.00222 Beta (8.9;6,599)
65þ y
All-risk 0.0117 0.00406–0.0193 Beta (8.9;750)
continued on next page
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Table 1 – continued
Costs parameters (2013 US$)
Outpatient visit without complication
0–17 y
All-risk 46 12–119 Lognormal (3.8;0.6) [18]
Outpatient visit otitis media
0–1 y
All-risk 106 31–270 Lognormal (4.7;0.55) [18]
2–4 y
All-risk 114 31–275 Lognormal (4.7;0.55)
5–17 y
All-risk 129 42–337 Lognormal (4.9;0.53)
Outpatient visit pneumonia or other complication
0–1 y
All-risk 246 85–983 Lognormal (5.5;0.63) [18]
2–4 y
All-risk 122 38–458 Lognormal (4.8;0.64)
5–17 y
All-risk 150 97–691 Lognormal (5.0;0.50)
Outpatient visit
18–49 y
NHR 158 149–168 Lognormal (5.0;0.03) [4]
HR 918 854–985 Lognormal (6.8;0.036)
50–64 y
NHR 190 171–210 Lognormal (5.2;0.04)
HR 928 895–962 Lognormal (6.8;0.018)
65þ y
NHR 306 279–335 Lognormal (5.7;0.03)
HR 603 586–620 Lognormal (6.4;0.015)
Hospitalization
0–1 y
NHR 7,650 6,314–8,985 Lognormal (8.9;0.090) [18]
HR 9,835 2,550–28,667 Lognormal (9.2;0.62)
2 y
NHR 6,193 3,036–14,813 Lognormal (8.7;0.40)
HR 9,107 3,278–41,769 Lognormal (9.1;0.65)
3–4 y
NHR 6,678 2,671–15,057 Lognormal (8.8;0.4)
HR 12,385 3,278–41,769 Lognormal (9.4;0.65)
5–17 y
NHR 7,770 485–43,348 Lognormal (9.0;1.1)
HR 10,443 2,671–62,775 Lognormal (9.3;0.81)
18–49 y
NHR 24,076 15,229–36,229 Lognormal (10;0.22) [4]
HR 60,419 40,398–86,971 Lognormal (11;0.20)
50–64 y
NHR 28,245 16,957–44,288 Lognormal (10;0.24)
HR 52,300 45,058–60,369 Lognormal (11;0.075)
65þ y
NHR 14,501 11,972–17,398 Lognormal (9.6;0.095)
HR 21,207 19,554–22,960 Lognormal (10;0.041)
Medical cost per death
0-17 y
NHR 36,486 16,985–68,971 Lognormal (10;0.36) [4]
HR 339,249 66,379–1,054,158 Lognormal (12;0.71)
18–49 y
NHR 96,647 19,663–294,799 Lognormal (11;0.69)
HR 96,082 25,337–256,950 Lognormal (11;0.59)
50–64 y
NHR 150,124 41,801–389,784 Lognormal (12;0.57)
HR 150,462 58,406–320,894 Lognormal (12;0.43)
65þ y
NHR 53,109 34,851–77,625 Lognormal (11;0.20)
HR 41,794 35,909–48,365 Lognormal (11;0.076)
OTC medication
0–2 y
All-risk 3.3 1.7–6.6 Lognormal (1.2;0.35) [4,18,27]
3–4 y
All-risk 4.9 2.5–10 Lognormal (1.6;0.35)
5–11 y
All-risk 6.5 3.3–13 Lognormal (1.9;0.35)
12–17 y
All-risk 3.0 1.5–6.1 Lognormal (1.1;0.35)
18þ y
All-risk 3.8 1.0–10 Lognormal (1.2;0.61)
continued on next page
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Table 1 – continued
Lost workdays: No complication*
0–4 y
All-risk 1 0.50–1.5 Gamma (3.8;0.26) [4]
5–17 y
All-risk 0.5 0.25–0.75 Gamma (3.8;0.13)
18–49 y
All-risk 0.5 0.25–0.75 Gamma (3.8;0.13)
50–64 y
All-risk 0.5 0.25–0.75 Gamma (3.8;0.13)
65þ y
All-risk 1 0.50–1.5 Gamma (3.8;0.26)
Lost workdays: Outpatient visit*
0–4 y
NHR 1 0.50–1.5 Gamma (3.8;0.26) [4]
HR 6 3.0–9.0 Gamma (3.8;1.6)
5–17 y
NHR 1 0.50–1.5 Gamma (3.8;0.26)
HR 4 2.0–6.0 Gamma (3.8;1.0)
18–49 y
NHR 1 0.50–1.5 Gamma (3.8;0.26)
HR 2 1.0–3.0 Gamma (3.8;0.52)
50–64 y
NHR 2 1.0–3.0 Gamma (3.8;0.52)
HR 4 2.0–6.0 Gamma (3.8;1.0)
65þ y
NHR 3 1.5–4.5 Gamma (3.8;0.78)
HR 7 3.5–11 Gamma (7;1.8)
Lost workdays: Hospitalization*
0–4 y
NHR 8 4.0–12 Gamma (3.8;2.1) [4]
HR 31 16–47 Gamma (31;8.1)
5–17 y
NHR 9 4.5–14 Gamma (3.8;2.3)
HR 23 12–35 Gamma (23;6.0)
18–49 y
NHR 12 6.0–18 Gamma (3.8;3.1)
HR 21 11–32 Gamma (21;5.5)
50–64 y
NHR 13 6.5–20 Gamma (3.8;3.4)
HR 24 12–36 Gamma (24;6.2)
65þ y
NHR 13 6.5–20 Gamma (3.8;3.4)
HR 18 9.0–27 Gamma (18;4.7)
Cost of lost workday
18–49 y
All-risk 83 NA NA [16,36]
50–64 y
All-risk 86 NA NA
65–75 y
All-risk 12 NA NA
Caregiver
All-risk 93 NA NA
Incremental vaccine price
6 mo–11 y 5.43 NA NA [28,29]
12–17 y 5.44 NA NA
418 y 5.36 NA NA
Health effects
QALY loss children o18 y
Episode of inﬂuenza, uncomplicated All-risk 0.005 0.002–0.009 Gamma (7.8;0.00064) [37]
Episode of otitis media
All-risk 0.042 0.023–0.065 Gamma (15;0.0027) [38]
Episode of pneumonia or other hospitalized complication
All-risk 0.046 0.027–0.071 Gamma (17;0.0027)
Hospitalization for pneumonia or other respiratory condition due to inﬂuenza
All-risk 0.076 0.054–0.100 Gamma (42;0.0018)
QALY loss adults
Episode of inﬂuenza, uncomplicated
All-risk 0.007 0.0054–0.0086 Normal (0.007;0.0008) [40]
Hospitalized inﬂuenza
All-risk 0.013 0.010–0.016 Normal (0.013;0.0015) [40,41]
DSA, deterministic sensitivity analysis; HR, high risk; NA, not available/applicable; NHR, non–high risk.
* A range of deterministic value 50% was used as 95% conﬁdence interval.
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level data from four clinical trials in which data on quality of
life (QOL) of ambulatory patients with laboratory-conﬁrmed
inﬂuenza were collected for 7 days using the visual analogue
scale score [40]. The QALY loss of an adult with inﬂuenza-
related hospitalization was estimated to be 1.8 times higher
than that of an ambulatory patient on the basis of a QOL
assessment among patients with clinically diagnosed inﬂuenza
in Belgium using the standardized 12-Item Short Form Survey
(SF-12)[41]. The number of LYs lost because of inﬂuenza-related
deaths was calculated by estimating remaining life expect-
ancies at the age of death using life tables [42]. LYs were
transformed to QALYs by adjusting these with baseline age-
speciﬁc QOL estimates [43].
Cost-Effectiveness
A time horizon of 20 years was used (week 30 of 2014 to week 29
of 2034) to cover ﬂuctuations in inﬂuenza disease between
seasons regarding, for example, attack rate, dominant strains,
and vaccine mismatches. Cumulative direct costs, indirect costs,
LYs lost, and QALYs lost were determined for both alternative
vaccines over the full time horizon. The incremental cost-
effectiveness ratios (ICERs) of shifting from TIV to QIV were then
calculated by dividing the net difference in costs by the net
difference in QALYs or LYs. To take time preferences into
account, future costs and health effects were annually dis-
counted at a rate of 3% [30].
Sensitivity Analysis
A deterministic sensitivity analysis was performed to vary to
the upper and lower bounds of the 95% conﬁdence interval (CI)
parameters considered of main interest (Table 1). For probabil-
ities and costs derived from Prosser et al. [18], we interpreted
the presented ranges as 95% CIs. SDs of costs derived from
Molinari et al. [4] were used to estimate 95% CIs. Results of the
deterministic sensitivity analysis were presented in a tornado
diagram.
Scenario analysis was performed to explore the effect of
alternative plausible inputs on cost-effectiveness outcomes. Con-
cerning parameters of the dynamic model, vaccine efﬁcacy (range
20% to þ20% of base-case efﬁcacy), vaccine coverage (range
20% to þ20% of base- case coverage), cross-protection against
opposite B lineage (range 40%–95% of matched vaccine efﬁcacy),
and duration of natural protection (6–18 years) were explored.
For the economic model, there were higher risks of hospital-
ization and mortality for the HR group than for the NHR group
[44–46]. Concerning health effects, alternative QALY loss assump-
tions as estimated by Sander et al. [47] were explored in the
model. Also, assumptions on calculations of the productivity
losses were varied by excluding the elasticity of adjustment
factor and increasing the friction period to 23 weeks, according
to Dutch cost-effectiveness guidelines [32], and a scenario using
the human capital approach. Here, lost earnings in all remaining
LYs till retirement were counted, ranging from $235,294 for the
age group of 65þ years to $1,739,727 for the age group of 18 to 49
years [4]. Finally, discount rates were varied, using 5% for both
costs and health effects and a scenario with 3% for costs and 0%
for health effects.
A probabilistic sensitivity analysis (PSA) was performed to
analyze the robustness of the results. Parameters of the dynamic
model involved in the PSA were probability of inﬂuenza infection
(β) with B Yamagata and B Victoria, cross-protection due to
natural infection and due to vaccination, duration of protection
after natural infection, weight of seasonal forcing, and duration
of the infectious period. Sampling was performed from theestimated posterior distributions of the listed parameters whose
95% high-density intervals are given in Table 1. In addition, plots
of the posterior of these parameters are given in the Supplemen-
tal Materials (see Appendix Fig. 1 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2016.05.012). Parameter
distributions in the economic model were deﬁned using means
and SDs as presented in Table 1. A total of 1000 iterations were
done and for each combination of parameters, the results were
presented in a cost-effectiveness plane. A cost-effectiveness
acceptability curve was generated to show the proportion of
cost-effective simulations over a range of willingness-to-pay
thresholds.Results
Health Outcomes, Costs, and Cost-Effectiveness
The impact of shifting from TIV to QIV on health outcomes and
costs is presented in Table 2. Over the next 20 years, shifting to
QIV will decrease the number of inﬂuenza B cases by 16.0
million (27.2%). Annual average numbers of prevented inﬂu-
enza B cases by age group can be found in Appendix Table 2 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2016.05.012. Consequently, this will avoid 6.1 million out-
patient visits, 137,645 hospitalizations, and 16,199 deaths, a
reduction of 29.4%, 30.4%, and 31.7%, respectively. In addition,
a total of 99,558 QALYs will be gained because of reduced
inﬂuenza illness and 113,190 QALYs because of averted inﬂu-
enza deaths. Concerning costs, shifting to QIV leads to an
increase of $11.6 billion in vaccine costs; however, $1.5 billion
in outpatient visit costs, $2.5 billion in hospitalization costs,
and $0.8 billion in costs of inﬂuenza-related deaths would be
saved. From the societal perspective, an additional $0.8 billion
of productivity losses and $0.05 billion in over-the-counter
medication costs are estimated to be saved. Table 3 presents
the incremental costs, health effects, and ICERs of QIV versus
TIV. The incremental costs of shifting from TIV to QIV are $6.7
billion and $5.8 billion from the TPP perspective and the
societal perspective, respectively. Consequently, a total of
212,722 QALYs and 143.7 LYs will be gained. This results in
ICERs of $31,385/QALY gained from the TPP perspective and
$27,411/QALY gained from the societal perspective. Regarding
LYs, the ICER is $46,477 per LY gained (TPP) and $40.591 per LY
gained (societal).
Univariate Sensitivity Analysis
The deterministic sensitivity analysis shows that the ICER was
most sensitive to the probability of death (Fig. 2A). Two further
parameters with high impact on the ICER were the probabilities
of hospitalization and the QALY losses attributed to inﬂuenza
illness. The scenario analysis demonstrated that the ICER was
most sensitive to the level of cross-protection (Fig. 2B). Decreas-
ing the cross-protection from 70% to 40% of vaccine efﬁcacy
changed the ICER to cost saving, whereas increasing the cross-
protection to 95% of vaccine efﬁcacy resulted in an ICER of
$297,000/QALY gained. Quantifying productivity losses using the
human capital approach instead of friction methods approach
decreased the ICER to $15,000/QALY gained. When QALY losses
due to inﬂuenza illness were used as presented by Sander et al.
[47], the ICER decreased to $15,700/QALY gained.
Altering the incremental vaccine price of QIV over TIV 25%
downward and upward resulted in ICERs of $13,840 and $40,991/
QALY gained, respectively. A threshold analysis estimated that
an incremental price of $7.63 rendered an ICER equal to $50,000/
QALY gained.
Table 2 – Health outcomes and costs of replacement of TIV by QIV in the United States over the next 20 y (2014–
2034).
Outcomes TIV QIV Difference
Clinical outcomes
Total number of symptomatic B cases (input from dynamic transmission model) 54,752,913 38,769,820 15,983,094
Total number of patients with outpatient visit 20,765,647 14,659,055 6,106,592
Total number of hospitalizations 452,440 314,795 137,645
Total number of deaths 51,118 34,919 16,199
Health effects
Total QALYs lost because of inﬂuenza illness 324,533 224,975 99,558
Total QALYs lost because of inﬂuenza-related death 348,694 235,504 113,190
Total life-years lost because of inﬂuenza-related death 441,894 298,227 143,667
Costs ($)
Vaccination 21,533,371,885 33,084,640,683 11,551,268,798
Outpatient visit 5,047,241,705 3,499,717,979 1,547,523,725
Hospitalized 8,065,030,717 5,538,868,166 2,526,162,550
Death 2,461,272,640 1,660,860,902 800,411,738
Productivity losses 2,593,650,999 1,797,327,693 796,323,306
OTC medications 161,308,724 112,012,536 49,296,188
OTC, over the counter; QALY, quality-adjusted life-year; QIV, quadrivalent inﬂuenza vaccine; TIV, trivalent inﬂuenza vaccine.
Costs and health effects discounted at 3%.
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inﬂuential parameters, cross-protection of vaccine efﬁcacy
against matched strain and vaccine efﬁcacy, is presented in
Figure 2. Cost-saving ICERs were obtained when cross-
protection was 50% or less of the vaccine efﬁcacy (Fig. 2C).
Variation of the vaccine efﬁcacy within 20% of the base-case
value resulted in an ICER ranging between $10,983 and 35,620/
QALY gained (Fig. 2D).Probabilistic Sensitivity Analysis
The PSA demonstrated that the cost-effectiveness results are
robustly scattered in the northeastern quadrant of the cost-
effectiveness plane (Fig. 3A). The PSA demonstrated that 97.2%
and 100% of the simulations were cost-effective from the societalTable 3 – Incremental cost-effectiveness results.
Outcome T
Total health care costs ($) 3
Total health care costs ($) (undiscounted) 4
Total health care costs þ societal costs ($) 3
Total health care costs þ societal costs ($) (undiscounted) 5
Total QALY loss 6
Total QALY loss (undiscounted) 1
Life-years loss 4
Life-years loss (undiscounted) 8
ICER ($/QALY gained)
TPP perspective –
TPP perspective (undiscounted) –
Societal perspective –
Societal perspective (undiscounted) –
ICER ($/life-year gained)
TPP perspective
TPP perspective (undiscounted)
Societal perspective
Societal perspective (undiscounted)
Numbers include a discount rate of 3% unless otherwise stated.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-
vaccine; TPP, third-party-payer.perspective using a willingness-to-pay threshold of $50,000/QALY
and $100,000/QALY, respectively (Fig. 3B). From the TPP perspec-
tive, these proportions were 94.6% and 100%, respectively.Discussion
Our results indicate that shifting from TIV to QIV is expected to
reduce the health burden of inﬂuenza B over the next 20 years
by 27.2% (16.0 million inﬂuenza B cases). This would prevent
6.1 million outpatient visits, 137,645 hospitalizations, and 16,199
deaths. Moreover, our analysis has demonstrated that QIV is a
cost-effective alternative, with ICERs of $31,385 and $27,411 per
QALY gained from the TPP perspective and the societal perspec-
tive, respectively. The PSA showed that the results were robust,IV QIV Incremental
7,106,916,946 43,784,087,731 6,677,170,784
9,312,653,802 58,204,478,071 8,891,824,269
9,861,876,669 45,693,427,960 5,831,551,291
3,012,885,962 60,815,765,930 7,802,879,968
73,227 460,480 212,748
,092,072 760,040 332,032
41,894 298,227 143,667
33,130 573,936 259,194
– 31,385
– 26,780
– 27,411
– 23,500
46,477
34,306
40,591
30,104
year; QIV, quadrivalent inﬂuenza vaccine; TIV, trivalent inﬂuenza
Fig. 2 – Univariate sensitivity analysis using the societal perspective. (A) Deterministic sensitivity analysis. Parameters were
varied within their 95% conﬁdence intervals. (B) Scenario analysis using the societal perspective. The y-axis shows the
various scenarios explored in the model. A 85% cross-protection was shown instead of 95% cross-protection in order to
improve readability of the ﬁgure (shown with asterisk). Using 95% cross-protection, the ICER was US $297,000/QALY gained.
(C) Univariate sensitivity analysis of the level of cross-protection. (D) Univariate sensitivity analysis of the level of vaccine
efﬁcacy. ICER, incremental cost-effectiveness ratio, OTC, over-the-counter, QALY, quality-adjusted life-year.
Fig. 3 – Probabilistic sensitivity analysis of quadrivalent inﬂuenza vaccine versus trivalent inﬂuenza vaccine over a time
period of 20 years (1000 simulations). (A) Cost-effectiveness plane of the societal perspective. Third-party payer’s (TPP’s)
perspective was not shown because of a high level of overlap. (B) Cost-effectiveness acceptability curve of the societal
perspective (normal line) and the TPP perspective (dashed line).
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V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 9 6 4 – 9 7 5 973given that more than 94% of the simulations were below a
threshold of $50,000/QALY gained and all simulations were below
$100,000/QALY gained. Variables with a high impact on the ICER
were level of cross-protection against opposite B lineage, vaccine
efﬁcacy, vaccine price, and probability of death given sympto-
matic inﬂuenza.
So far, two economic comparisons of QIV versus TIV in the
United States have been conducted, involving a cost-beneﬁt
[10,11] and a cost-effectiveness analysis [12]. The cost-beneﬁt
analysis used data on clinical outcomes (symptomatic cases,
hospitalizations, and deaths) from a retrospective study by Reed
et al. [9]. This study, using a static model, estimated that during
the seasons 1999-2000 to 2008-2009 QIV could have reduced the
number of inﬂuenza cases on average by 342,700 per year,
resulting in annual reductions of 2,144 hospitalizations and 137
deaths [9]. Our dynamic model estimated the number of pre-
vented inﬂuenza cases to be more than twice as high (mean
yearly reduction of 799,155 inﬂuenza cases), which might be at
least partly explained by our model’s ability to account for herd
immunity. Other differences as compared with Reed et al. [9] are
that our analysis is age-stratiﬁed and takes into account the
existing population immunity and cross-protection against the
mismatched B strain. Regarding health-related outcomes, it is
striking that our estimate on the number of inﬂuenza deaths is
relatively high as compared with Reed et al. [9] (810 vs. 137). This
might be related to the fact that we used inﬂuenza-related
mortality estimates based on International Classiﬁcation of
Diseases-9 codes of all underlying respiratory and circulatory
diseases, whereas Reed et al. [9] restricted the analysis to only
those causes of death corresponding to International Classiﬁcation
of Diseases-9 codes of inﬂuenza and pneumonia only. Because it
has previously been suggested that including only respiratory
categories might result in an underestimation of deaths attrib-
uted to inﬂuenza [48], we chose to use mortality estimates that
included all underlying respiratory and circulatory diseases. The
corresponding cost-beneﬁt analysis by Lee et al. [10,11] estimated
the mean incremental costs per inﬂuenza case averted at $1218,
using the TPP perspective and an incremental vaccine price of $5.
Applying exactly the same vaccine price difference, we estimated
a lower incremental cost per case of $488. This might be related
to the higher hospitalization costs used in our analysis, although
we had no access to speciﬁed cost data of the study of Lee et al.
[10,11].
The second economic analysis comparing QIV with TIV in the
United States was a cost-effectiveness analysis by Clements et al.
[12]. This study also used a static approach and estimates on
inﬂuenza incidence, vaccine efﬁcacy, and cross-protection, which
were similar to ours. Despite the different modeling approach, we
found similar reductions in hospitalizations and deaths. More-
over, the incremental costs of QIV over TIV were comparable
from a TPP perspective ($340 million by Clements et al. [12] vs.
$445 million in our study [undiscounted]) and even closer from a
societal perspective ($327 million by Clements et al. [12] vs. $390
million in our study [undiscounted, productivity losses of death
excluded for consistency]). Because Clements et al. [12] did not
account for herd protection and did not count QALY losses due to
inﬂuenza illness, but only due to deaths, we found a higher QALY
gain in our study (9584 vs. 3593). This explains our lower
estimated cost-effectiveness ratio of $27,415/QALY gained as
compared with the one by Clements et al. [12] ($90,301/QALY
gained). A comparison of QIV with TIV in the United Kingdom
found an ICER of È27,378/QALY gained ($44,300) for the TPP
perspective, which is also in the range of what we found [49].
Important differences to our analysis are the static approach
they used.
A strong point of this study was the use of a dynamic trans-
mission model, which provides the ability to account for changes inthe force of infection arising from the reduction in the prevalence of
infected individuals brought about by vaccination. Static models, in
contrast, use a ﬁxed force of infection, which makes them able to
capture only the impact of direct protection at the very start of an
inﬂuenza season. As soon as direct protection of vaccination
inﬂuences the prevalence of infectious cases, a change in the force
of infection occurs. Static models then cease to quantify the direct
protection of vaccination correctly, making the value of a direct
comparison between the static and dynamic modeling approaches
of limited value only. Moreover, because the force of infection
inﬂuences the direct and indirect impact of the vaccination in our
analytic context, this comparison is further hampered. Yet, if
comparing static and dynamic models, the most valid comparison
might be between Reed et al. [9] (as already discussed above) and
results of our dynamic model previously shown in Crepey et al. [15],
because these studies cover the same time period (2001–2009). This
comparison shows that in this situation the dynamic model
predicted twice the number of inﬂuenza cases prevented per year
as compared with the static model (342,700 vs. 661,600).
As with any economic evaluation, our analysis is a simpliﬁ-
cation of the real world and we had to make some assumptions.
One simpliﬁcation of our model structure concerned the exclu-
sion of the use of antiviral medication (such as zanamivir and
oseltamivir). However, the efﬁcacy of antiviral medication was
included intrinsically in the probabilities of inﬂuenza-related
complications we used, as well as the costs of antiviral medi-
cations (including the “older” drugs amantadine and rimantidine)
that were included in the cost data of outpatient visits. Because
these cost data were based on the period 2001-2003, prescription
behavior may have changed in the meantime and could therefore
have an impact on our results. We expect this impact to be small,
however, because the univariate sensitivity analysis showed that
the outpatient visits’ costs had a minor impact on the ICER.
Second, we used probabilities of complications, cost estimates,
and QALY losses of inﬂuenza in general, because data speciﬁc to
inﬂuenza type B were scarce. However, literature so far did not
show signiﬁcant differences in clinical burden between inﬂuenza
A and inﬂuenza B [50]. Furthermore, estimates on probabilities to
a clinical event stratiﬁed between HR and NHR population were
scarce. Therefore, the inﬂuenza-related probabilities of outpa-
tient visits for HR populations had to be based on assumptions
taken from earlier studies [4,18]. For the probability of hospital-
ization and death, we applied the same risk for the HR population
as for the NHR population, in the absence of data. Because HR
individuals tend to have a higher risk of hospitalization or death
[45,46,51] and higher treatment costs [4], our assumptions can be
considered as conservative in this regard. Also, we did not
explicitly take into account potential vaccination with live-
attenuated inﬂuenza vaccine (LAIV) in our model. The current
Advisory Committee on Immunization Practices recommenda-
tions do however not prefer LAIVs over inactivated inﬂuenza
vaccines because efﬁcacy estimates were found to be similar [52].
Concerning costs, incremental vaccine costs of QIV over TIV were
based on inactivated vaccine price differences, whereas the CDC
list-price of trivalent-LAIV and quadrivalent-LAIV remained the
same [53,54]. This might result in an overestimation of the
incremental vaccine costs of QIV over TIV, which can therefore
be regarded as a conservative approach in our analysis. Finally,
we assumed a complete one-off switch from TIV to QIV for all age
groups, whereas in reality this switch might be gradual. However,
adoption of QIV in the United States has been widespread,
although no public data by age group are available at the
moment. Moreover, full-scale adoption of QIV might again be
considered a conservative approach for estimating the ICER as
compared with targeted adoption.
No ofﬁcial willingness-to-pay threshold exists for the United
States; however, $50,000/QALY gained has been cited in most
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 9 6 4 – 9 7 5974articles [55]. Our study demonstrates that shifting to QIV would
be a cost-effective intervention in the base case applying this
threshold. Another approach, which has recently been proposed
by the World Health Organization, is to relate the cost-
effectiveness threshold to other health program alternatives to
judge whether an intervention offers good value for the health
care budget [56]. In the United States, multiple vaccines have
been added to the CDC’s vaccination schedule during the last
decade. Examples of these recommended vaccines and their cost-
effectiveness are pneumococcal conjugate vaccine for 65þ-year-
olds (ICER $62,065/QALY) [57], tetanus toxoid, diphtheria toxoid
and acellular pertussis for 65þ-year-olds ($13,000–$328,000/QALY)
and for pregnant women ($414,523/QALY) [58,59], meningococcal
conjugate vaccine for 11-year-olds þ catch-up 10- to 17-year-olds
($88,000/QALY) [60], and human papillomavirus for 12-year-old
girls ($3,000–45,000/QALY) and for 12-year-old boys ($20,000–
250,000/QALY) [61]. The cost-effectiveness of QIV is at least as
favorable as all aforementioned vaccines.Conclusions
Our model estimates that replacement of TIV by QIV would
reduce the number of inﬂuenza B cases by 27.2% (16 million
cases) over the next 20 years in the United States. This would
avoid 6.1 million outpatient visits, 137,645 hospitalizations, and
16,199 deaths. In the base case, the ICER was estimated at
$31,385/QALY gained from the TPP perspective and $27,411/QALY
gained from the societal perspective. Sensitivity analyses dem-
onstrate that the results are robust with similar cost-
effectiveness results over various ranges of assumptions. QIV
could be considered to be a cost-effective intervention from both
the TPP perspective and the societal perspective applying a cost-
effectiveness threshold of $50,000/QALY gained.Supplementary Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/j.
jval.2016.05.012 or, if a hard copy of article, at www.valueinhealth
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